Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization by Pinheiro, Céline et al.
Pinheiro et al. Journal of Translational Medicine 2014, 12:118
http://www.translational-medicine.com/content/12/1/118RESEARCH Open AccessCharacterization of monocarboxylate transporters
(MCTs) expression in soft tissue sarcomas: distinct
prognostic impact of MCT1 sub-cellular
localization
Céline Pinheiro1,2,3,4, Valter Penna5, Filipa Morais-Santos1,2, Lucas F Abrahão-Machado6, Guilherme Ribeiro4,
Emílio C Curcelli7, Marcus V Olivieri5, Sandra Morini6, Isabel Valença8, Daniela Ribeiro8, Fernando C Schmitt9,10,11,
Rui M Reis1,2,4 and Fátima Baltazar1,2*Abstract
Background: Soft tissue sarcomas (STSs) are a group of neoplasms, which, despite current therapeutic advances,
still confer a poor outcome to half of the patients. As other solid tumors, STSs exhibit high glucose consumption
rates, associated with worse prognosis and therapeutic response. As highly glycolytic tumors, we hypothesized that
sarcomas should present an increased expression of lactate transporters (MCTs).
Methods: Immunohistochemical expression of MCT1, MCT2, MCT4 and CD147 was assessed in a series of 86 STSs
and the expression profiles were associated with patients’ clinical-pathological parameters.
Results: MCT1, MCT4 and CD147 were mainly observed in the plasma membrane of cancer cells (around 60% for
MCTs and 40% for CD147), while MCT2 was conspicuously found in the cytoplasm (94.2%). Importantly, we
observed MCT1 nuclear expression (32.6%). MCT1 and MCT4, alone or co-expressed with CD147 in the plasma
membrane, were associated with poor prognostic variables including high tumor grade, disease progression and
shorter overall survival. Conversely, we found MCT1 nuclear expression to be associated with low grade tumors and
longer overall survival.
Conclusions: The present work represents the first report of MCTs characterization in STSs. We showed the original
finding of MCT1 expression in the nucleus. Importantly, opposite biological roles should be behind the dual
sub-cellular localization of MCT1, as plasma membrane expression of MCT1 is associated with worse patients’
prognosis, while nuclear expression is associated with better prognosis.
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Soft tissue sarcomas (STSs) are an extremely heterogeneous
group of rare tumors that arise predominantly from the
embryonic mesoderm [1]. STSs can occur in any soft tissue
in the body, and may have different etiologies, including ex-
ternal radiation therapy and occupational exposure to cer-
tain chemicals such as herbicides [1,2]. Despite some* Correspondence: fbaltazar@ecsaude.uminho.pt
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unless otherwise stated.therapeutic improvements, metastasis and death remain a
significant problem in half of STS patients, who present
advanced disease [1]. Recent advances on the knowledge
related to the oncogenic mechanisms underlying sarcoma-
genesis will hopefully translate into more effective therap-
ies [1,2].
It has been shown that most sarcomas exhibit a strong
glycolytic phenotype and this phenomenon supplies the
rationale for positron emission tomography imaging of STS
using 18F-fluorodeoxyglucose (FDG-PET) [3]. FDG-PET
measurements in STS allow primary and recurrent detec-
tion of intermediate and high-grade tumors [4], beingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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proliferative activity, MIB labeling index, and p53 over-
expression [5]. Additionally, FDG-PET is proposed as a
modality to monitor treatment response in high-grade
STS patients [3,6,7], as quantitative FDG-PET is signifi-
cantly more accurate than size-based criteria at assessing
STS response to neoadjuvant therapy [6,7].
The specific changes that occur in tumor microenviron-
ment have been recently identified as key components in
carcinogenesis. In fact, the reprogramming of energy me-
tabolism, with special focus on the Warburg phenomenon,
i.e., the preference for the glycolytic phenotype even in the
presence of oxygen, has been recently included as a “new”
hallmark of cancer [8]. Since the hyper-glycolytic phenotype
will generate high amounts of lactate inside cancer cells,
monocarboxylate transporters (MCTs) play an important
role in the extrusion of lactate, contributing to the mainten-
ance of the intracellular pH of tumor cells. MCTs are trans-
membrane proteins, which are encoded by the family of
genes SLC16A, which presently include 14 members. How-
ever, only the first four members, MCT1-4, are able to
transport lactate and other monocarboxylates across mem-
branes, coupled with a proton [9]. MCT1 has a ubiquitous
distribution in human tissues, being involved in both up-
take and efflux of monocarboxylates from cells, and is con-
sidered an intermediate affinity isoform. MCT2 is a high
affinity transporter, being adapted to the uptake of mono-
carboxylates into cells, and is mostly found in tissues that
use lactate as a respiratory fuel. MCT3 has a very restricted
distribution, having been identified in the retinal pigment
and choroid plexus epithelia. MCT4 is known as a low af-
finity transporter and has been observed particularly in
highly glycolytic tissues, where is essentially responsible for
lactate efflux. MCT1 and MCT4 are the best studied iso-
forms in cancer, as being responsible for lactate transport
across the plasma membrane [9].
However, the role of MCTs in solid tumors is still far
from being fully characterized [10]. Although pointed
out as potential therapeutic targets [11-15], more infor-
mation on MCTs’ expression in human solid tumors is
needed to further translate knowledge into the clinic
context. Some information about the expression and
clinical-pathological significance of MCTs is provided
for various human tumors [10] like tumors from brain
[16], colon [17,18], breast [19], uterine cervix [20],
prostate [21] and lung [22], and the vast majority of
studies are focused on tumors of epithelial lineage, but
similar studies are lacking for other types of tumors.
In sarcomas, MCT1 expression was found in the pre-
crystalline cytoplasmic granules of 7 out of 10 alveolar
soft part sarcomas [23], while MCT1, MCT2 and
MCT4 mRNAs were found in the human rhabdomyo-
sarcoma cell line RD [24-26]. Therefore, studies on
MCT expression and clinical-pathological significancein sarcomas may contribute to the knowledge on the
biology of this tumor.
Therefore, the aim of this work was to assess the ex-
pression of MCT1, MCT2 and MCT4, and MCT1/4
chaperone CD147, in a series of sarcomas, and evaluate
their clinical-pathological significance.
Methods
Case selection
Eighty-six samples of soft tissue sarcomas were retrieved
from the Pathology archives of Barretos Cancer Hospital,
Barretos, São Paulo, Brazil. Relevant clinical-pathological
data available included patient’s age, gender and race,
tumor localization, diagnostic and grade (according to
the French Federation of Cancer Centers Sarcoma
Group (FNCLCC) [27]), cell lineage, presence of pleo-
morphic cells, disease progression, disease recurrence
and presence of metastasis, as specified in Table 1.
Moreover, follow-up information was available for 84 pa-
tients and overall survival was defined as the time
between the date of first consultation and the date of
last information or patient death. This study was ap-
proved by the local Ethics Committee (Barretos Cancer
Hospital; no. 331/2010).
Immunohistochemistry
MCT and CD147 detection
MCT1 immunohistochemistry was performed according to
the avidin-biotin-peroxidase complex method (R.T.U. VEC-
TASTAIN Elite ABC Kit (Universal), Vector Laboratories,
Burlingame, CA), with primary antibody for MCT1
(AB3538P, Chemicon International, Temecula, CA) diluted
1:200, as previously described [17]. Immunohistochemistry
for MCT2, MCT4 and CD147 was performed according to
the streptavidin-biotin-peroxidase complex principle (Ultra-
vision Detection System Anti-polyvalent, HRP, Lab Vision
Corporation, Fremont, CA), using primary antibodies raised
against MCT2 (sc-50322, Santa Cruz Biotechnology, Santa
Cruz, CA), MCT4 (sc-50329, Santa Cruz Biotechnology,
Santa Cruz, CA), and CD147 (18–7344, ZYMED Labora-
tories Inc., South San Francisco, CA), diluted 1:100, 1:500
and 1:750, respectively, as previously described [28]. Nega-
tive controls were performed by the use of appropriate
serum controls for the primary antibodies (N1699, Dako,
Carpinteria, CA). Colon carcinoma tissue was used as posi-
tive control for MCT1, MCT4 and CD147 while kidney
was used for MCT2. Tissue sections were counterstained
with hematoxylin and permanently mounted.
Immunohistochemical evaluation
Sections were scored semi-quantitatively for plasma mem-
brane expression as follows: 0: 0% of immunoreactive cells;
1: <5% of immunoreactive cells; 2: 5-50% of immunoreac-
tive cells; and 3: >50% of immunoreactive cells. Also,
Table 1 Clinical-pathological data of sarcomas’ patients
Variable n %
Age
>51 48 56.5
≤51 37 43.5
Gender
Female 33 38.8
Male 52 61.2
Race
Caucasian 63 74.1
Not Caucasian 22 25.9
Local
Lower extremities 63 73.3
Upper extremities 23 26.7
Diagnostic
Pleomorphic leiomyosarcoma 17 19.8
Myxoid/round cells liposarcoma 14 16.3
High grade undifferentiated pleomorphic sarcoma 12 14.0
Monophasic fibrous synovial sarcoma 9 10.5
Myxofibrosarcoma 7 8.1
Malignant peripheral nerve sheath tumor 7 8.1
Low grade fibromyxoid sarcoma 3 3.5
Poorly differentiated synovial sarcoma 2 2.3
High grade myofibroblastic sarcoma 2 2.3
Clear cell sarcoma 1 1.2
Biphasic synovial sarcoma 1 1.2
Fibrosarcoma 1 1.2
Angiomatoid histiocytoma 1 1.2
Infantile fibrosarcoma 1 1.2
Well differentiated liposarcoma 1 1.2
Undifferentiated liposarcoma 1 1.2
Pleomorphic liposarcoma 1 1.2
Acral myxoinflammatory fibroblastic sarcoma 1 1.2
Low grade myofibroblastic sarcoma 1 1.2
Giant-cell-rich high grade undifferentiated
pleomorphic sarcoma
1 1.2
Malignant solitary fibrous tumor 1 1.2
Alveolar sarcoma 1 1.2
Cell lineage
Fibroblastic/myofibroblastic 28 32.5
Smooth muscle 17 19.8
Lipogenic 17 19.8
Peripheral nerve 7 8.1
Miscellaneous 17 19.8
Table 1 Clinical-pathological data of sarcomas’ patients
(Continued)
Cellular pleomorphism
Absence of pleomorphic cells 54 62.8
Presence of pleomorphic cells 32 37.2
Grade
Low grade (I) 30 32.2
High grade (II e III) 63 67.7
Disease progression
No 25 30.9
Yes 56 69.1
Disease recurrence
Absent 48 57.1
Present 36 42.9
Metastasis
Absent 44 52.4
Present 40 47.6
Significant values are shown in bold.
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lows: 0: negative; 1: weak; 2: intermediate; and 3: strong.
The final score was defined as the sum of both parameters
(extension and intensity), and grouped as negative (score 0
and 2) and positive (score 3–6), as previously described
[17]. Protein expression in other cellular localizations was
also assessed. Two independent pathologists (LM and FCS)
performed immunohistochemical evaluation blindly and
discordant results were discussed in a double-head micro-
scope in order to determine the final score.
Immunofluorescence
MLS-1765 cells, a myxoid liposarcoma cell line provided
by Dr. Pierre Åman (Lundberg Laboratory for Cancer Re-
search, Department of Pathology, Sahlgrenska Academy at
Göteborg University, Göteborg, Sweden), were subjected
to immunofluorescence to determine the subcellular
localization of MCT1, MCT4 and CD147. Cells were
seeded on glass cover slips and fixed after 24 h with 4%
paraformaldehyde in PBS, pH 7.4, during 20 min. After-
wards, cells were permeabilized with 0.2% Triton X-100
for 10 min, blocked with 1% BSA solution for further
10 min and incubated with the same primary antibodies
used for immunohistochemistry, for 1 h. Upon 1 h incuba-
tion with the secondary antibody (Fluorophore Alexa 488,
Invitrogen, Life Technologies, Grand Island, NY, USA),
cells were stained with Hoechst 33342 and mounted on
slides using Mowiol 4–88 containing n-propylgallate. Be-
tween each step, cells were extensively rinsed 3 times with
PBS, pH 7.4. Images were obtained using a Zeiss LSM 510
Meta Confocal setup (Carl Zeiss, Oberkochen, Germany)
equipped with a plan-Apochromat 100×/1.4 oil objective.
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Nuclear and cytosolic proteins were extracted from MLS-
1765 cells, with a nuclear extraction kit (NXTRACT, Sigma-
Aldrich) according to the manufacturer’s instructions.
Protein quantification was performed according to the
Bio-Rad Dc Protein Assay (500–0113, Bio Rad) and Western
blot was performed as previously described [16]. Briefly, after
incubation with the primary polyclonal antibodies rabbit
anti-MCT1 (1:200 dilution; AB3538P; Chemicon Inter-
national), rabbit anti-Histone H3 (1:1000 dilution; ab1791,
Abcam), membranes were incubated with the respective sec-
ondary antibody coupled to horseradish peroxidase (Santa-
Cruz Biotechnology). The bound antibodies were visualized
by chemiluminescence (Supersignal West Femto kit; Pierce).Statistical analysis
Data were stored and analyzed using the IBM SPSS stat-
istical software (version 19, IBM Company, Armonk,
NY). All comparisons were examined for statistical sig-
nificance using Pearson’s chi-square (χ2) test and Fisher’s
exact test (when n < 5), being threshold for significance
p values <0.05. Overall survival curves were estimated by
the method of Kaplan-Meier and data compared using
the log rank test. Cases lacking one or more of the
clinical-pathological variables were not included in the
specific statistical analysis.A
ED
B
Figure 1 Representative immunohistochemical reactions for MCT1, M
undifferentiated pleomorphic sarcoma (fibroblastic/myofibroblastic cell line
solitary fibrous tumor (miscellaneous cell lineage) showing cytoplasmatic e
(peripheral nerve cell lineage) showing MCT4 expression in the plasma me
showing CD147 in the plasma membrane; (E and F) Myxoid/round cells lip
A-D and F: 400× magnification; E: 100× magnification.Results
Soft tissue sarcomas show nuclear expression of MCT1
A series of 86 cases of histologically confirmed soft tissue
sarcomas was analyzed for the immunohistochemical ex-
pression of the MCT isoforms 1, 2 and 4 as well as MCT1
and 4 chaperone, CD147. Overall, the expression of these
proteins was mainly found at the plasma membrane
(Figure 1), with the exception of MCT2 (Figure 1B), which
was only observed in the plasma membrane in one case.
MCT1 plasma membrane expression was depicted in 52
cases (60.5%, Figure 1A), MCT2 expression was found in
81 cases (94.2%), MCT4 was observed in the plasma mem-
brane of 49 cases (57.0%, Figure 1C), while CD147 was
found in 38 cases (44.2%, Figure 1D). Importantly, nuclear
expression of MCT1 was observed in 28 cases (32.6%,
Figure 1E and F). Additionally, a significant association be-
tween plasma membrane expression of MCT1/4 and
CD147 was found (Table 2).
Plasma membrane expression of MCT1 and MCT4 is
associated with poor prognostic features, while nuclear
expression of MCT1 is associated with good prognosis
Regarding the association between the clinical-pathological
features and the expression of the proteins herein analyzed,
many important associations were found (Tables 3 and 4).
Firstly, despite the lack of statistical association, we ob-
served a tendency of MCT1 expression with cell lineage.F
C
CT2, MCT4 and CD147 in soft tissue sarcomas. (A) High grade
age) showing MCT1 plasma membrane expression; (B) Malignant
xpression of MCT2; (C) Malignant peripheral nerve sheath tumor
mbrane; (D) Myxoid/round cells liposarcoma (lipogenic cell lineage)
osarcoma (lipogenic cell lineage) showing nuclear expression of MCT1.
Table 2 Association of CD147 with MCT1 and MCT4
expression in sarcoma samples
n CD147 positive (%) p
MCT1 <0.001
Negative 34 3 (8.8)
Positive 52 36 (67.3)
MCT4 0.005
Negative 37 10 (27.0)
Positive 49 29 (57.1)
Significant values are shown in bold.
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presence of pleomorphic cells (p = 0.034), high grade tu-
mors (p < 0.001) and disease progression (p = 0.018). Im-
portantly, nuclear expression of MCT1, was associated
with cell lineage (p < 0.001), being evidently more fre-
quently observed in the lipogenic lineage. Additionally,
MCT1 nuclear expression was significantly associated
with the absence of pleomorphic cells (p = 0.010) and low
grade tumors (p < 0.001) and showed a tendency to be
more frequent in patients without metastasis (p = 0.084)
and younger patients (p = 0.076). Concerning MCT4 ex-
pression, similar associations to the ones depicted for
MCT1 were found; MCT4 was more frequently expressed
in the smooth muscle lineage (p < 0.001), was associated
with the presence of pleomorphic cells (p = 0.009), high
grade tumors (p = 0.011) and showed a tendency to be
associated with disease progression (p = 0.060). CD147
expression alone was associated with disease progres-
sion (p = 0.020) and showed a tendency to be associated
with presence of pleomorphic cells (p = 0.083) and high
tumor grade (p = 0.076), associations that reached signifi-
cance when CD147 was evaluated in co-expression ei-
ther with MCT1 or MCT4. As the majority of cases
were positive for cytoplasmic expression of MCT2 and
only one showed plasma membrane expression, no statis-
tical analysis was performed for this protein.
Plasma membrane expression of MCT1 and MCT4 is
associated with shorter patient overall survival
Comparison of the survival rates between different expres-
sion phenotypes revealed an important association between
the proteins analyzed in this study and the survival odds
(Figure 2). Patients with either MCT1 or MCT4 plasma
membrane positive tumors showed a significantly higher
likelihood to present a lower overall survival than the nega-
tive cases; patients with MCT1 positive tumors showed a
median overall survival of 25.5 months versus 34.2 months
in the negative tumors (p = 0.021, Figure 2A), while patients
with MCT4 positive tumors showed a median overall sur-
vival of 22.9 months versus 34.8 months in negative tumors
(p = 0.003, Figure 2C). Importantly, MCT1 nuclear expres-
sion showed a border-line tendency to be associated withhigher overall survival, with positive cases showing a me-
dian overall survival of 35.9 months versus 25.0 months in
negative cases (p = 0.059, Figure 2B). A nearly significant re-
sult was also observed for CD147 (p = 0.067, Figure 2D),
nevertheless, co-expression of CD147 along with MCT4
(Figure 2F), but not MCT1 (Figure 2E), showed a signifi-
cant association with poorer overall survival, with patients
with double MCT4/CD147 positive tumors showing a me-
dian overall survival of 19.5 months versus 34.6 months in
the remaining group (p = 0.005).
MCT1 nuclear expression is also found in an in vitro
model of myxoid liposarcoma
To validate MCT1 expression in the nuclear compart-
ment, immunofluorescence for MCT1, MCT4 and
CD147 was performed in a sarcoma cell line represent-
ing the lineage with the highest frequency of MCT1 ex-
pression in the nucleus, the lipogenic lineage. As
observed in Figure 3, MLS-1765 cells have a strong, and
almost exclusive, expression of MCT1 in the nucleus.
This MCT1 nuclear expression was partly accompanied
by its chaperone CD147, which also seems to accumu-
late in the perinuclear region, while MCT4 was found
homogeneously distributed through the cell. To further
confirm the presence of MCT1 in the nucleus, we per-
formed cell fractionation, separating the nuclear from
the cytosolic fraction. As can be seen in Figure 4, the
main protein band of MCT1 is present in the nuclear
fraction, confirming the results of Figure 3.
Discussion
Recent studies show that FDG-PET may contribute for
precise grading and prognosis in different solid tumors,
including soft tissue sarcomas [5], as high grade tumors
show a much higher uptake of 18F-FDG due to a higher
glycolytic phenotype [3]. Also, it was recently described
that FDG-PET should be considered an important im-
aging modality for therapeutic monitoring in patients
with high-grade STS [6,7]. In this context, metabolic
characterization of STS emerges as a possibly relevant
approach for STS management, with therapeutic impli-
cations as early treatment decisions such as discon-
tinuation of chemotherapy in non-responding patients
could be based on FDG-PET criteria [7]. Importantly,
the hyperglycolytic phenotype present in this type of
tumors, similarly to other solid tumors, may be the
basis for the use of new directed therapeutic strategies
which are currently in clinical trials [29]. Therefore,
tumor metabolic characterization, including MCTs as
responsible for lactate efflux from highly glycolytic
cells, will have a relevant impact on predicting the
group of patients that will benefit the most from this
recent therapeutic approach and may have a prognostic
value.
Table 3 Association of MCT expression with the clinical-pathological parameters
Clinical-pathological data MCT1 (PM) MCT1 (nucleus) MCT4 (PM)
n Positive (%) p Positive (%) p Positive (%) p
Age 0.153 0.076 0.403
>51 48 32 (66.7) 12 (25.0) 29 (60.4)
≤51 37 19 (51.4) 16 (43.2) 19 (51.4)
Gender 0.716 0.174 0.463
Female 33 19 (57.6) 8 (24.2) 17 (51.5)
Male 52 32 (61.5) 20 (38.5) 31 (59.6)
Race 0.686 0.896 0.832
Caucasian 63 37 (58.7) 21 (33.3) 36 (57.1)
Not Caucasian 22 14 (63.6) 7 (31.8) 12 (54.5)
Local 0.586 0.439 0.154
Lower extremities 63 37 (58.7) 22 (34.9) 33 (52.4)
Upper extremities 23 15 (65.2) 6 (26.1) 16 (69.6)
Cell lineage 0.066 <0.001 <0.001
Fibroblastic/myofibroblastic 28 16 (57.1) 9 (32.1) 16 (57.1)
Smooth muscle 17 12 (70.6) 3 (17.6) 13 (76.5)
Lipogenic 17 6 (35.3) 13 (76.5) 2 (11.8)
Peripheral nerve 7 4 (57.1) 2 (28.6) 4 (57.1)
Miscellaneous 17 14 (82.4) 1 (5.9) 14 (82.4)
Cellular pleomorphism 0.034 0.010 0.009
Absence of pleomorphic cells 54 28 (51.9) 23 (42.6) 25 (46.3)
Presence of pleomorphic cells 32 24 (75.0) 5 (15.6) 24 (75.0)
Grade <0.001 <0.001 0.011
Low grade (I) 19 4 (21.1) 14 (73.7) 6 (31.6)
High grade (II e III) 67 48 (71.6) 14 (20.9) 43 (64.2)
Disease progression 0.018 0.865 0.060
No 25 10 (40.0) 8 (32.0) 10 (40.0)
Yes 56 39 (67.2) 20 (33.9) 35 (62.5)
Disease recurrence 0.847 0.640 0.204
Absent 48 29 (60.4) 15 (31.2) 24 (50.0)
Present 36 21 (58.3) 13 (36.1) 23 (63.9)
Metastasis 0.156 0.122 0.249
Absent 44 23 (52.3) 18 (40.9) 22 (50.0)
Present 40 27 (67.5) 10 (25.0) 25 (62.5)
PM- Plasma membrane.
Significant values are shown in bold.
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ing over 50 histological subtypes, which are often associ-
ated with unique clinical, prognostic and therapeutic
features [30]. Although some authors point to a lack of
association between FDG uptake and histological type
[4], others show that FDG uptake may differ significantly
among histologic subtypes, when tumors of all grades
were included [3]. Importantly, a low glycolytic pheno-
type was described in certain STS subtypes including tu-
mors from the lipogenic lineage [3], which supports thelow expression of MCT1 and MCT4 we found in the
plasma membrane of this sarcoma subtype. This is in ac-
cordance with the low tumor cellularity characteristic of
these tumors, which probably results in lower total
tumor glucose consumption [3]. The low glycolytic rates
shown by tumors from the lipogenic lineage could antici-
pate the expression of MCT2 in the plasma membrane in
a way to allow cancer cells to obtain energy from oxida-
tive phosphorylation, via uptake of other substrates like
lactate itself or pyruvate; however, MCT2 was expressed
Table 4 Association between CD147 plasma membrane expression, alone or co-expressed with MCT1, and the
clinical-pathological parameters
Clinical-pathological data CD147 CD147 +MCT1 CD147 +MCT4
n Positive (%) p Positive (%) p Positive (%) p
Age 0.498 0.583 0.308
>51 48 23 (47.9) 21 (43.8) 18 (37.5)
≤51 37 15 (40.5) 14 (37.8) 10 (27.0)
Gender 0.577 0.523 0.680
Female 33 16 (48.5) 15 (45.5) 10 (30.3)
Male 52 22 (42.3) 29 (38.5) 19 (34.6)
Race 0.562 0.976 0.511
Caucasian 63 27 (42.9) 26 (41.3) 22 (34.9)
Not Caucasian 22 11 (50.0) 9 (40.9) 6 (27.3)
Local 0.936 0.751 0.432
Lower extremities 63 28 (44.4) 25 (39.7) 19 (30.2)
Upper extremities 23 10 (43.5) 10 (43.5) 9 (39.1)
Cell lineage 0.878 0.694 0.071
Fibroblastic/myofibroblastic 28 13 (46.4) 12 (42.9) 12 (42.9)
Smooth muscle 17 6 (35.3) 6 (35.3) 5 (29.4)
Lipogenic 17 7 (41.2) 5 (29.4) 1 (5.9)
Peripheral nerve 7 3 (42.9) 3 (42.9) 2 (28.6)
Miscellaneous 17 9 (52.9) 9 (52.9) 8 (47.1)
Cellular pleomorphism 0.083 0.071 0.002
Absence of pleomorphic cells 54 20 (37.0) 18 (33.3) 11 (20.4)
Presence of pleomorphic cells 32 18 (56.2) 17 (53.1) 17 (53.1)
Grade 0.076 0.016 0.026
Low grade (I) 19 5 (26.3) 3 (15.8) 2 (10.5)
High grade (II e III) 67 33 (49.3) 32 (47.8) 26 (38.8)
Disease progression 0.020 0.016 0.070
No 25 6 (24.0) 5 (20.0) 4 (16.0)
Yes 56 29 (51.8) 27 (48.2) 21 (37.5)
Disease recurrence 0.949 0.847 0.840
Absent 48 21 (43.8) 19 (39.6) 15 (31.2)
Present 36 16 (44.4) 15 (41.7) 12 (33.3)
Metastasis 0.295 0.090 0.593
Absent 44 17 (38.6) 14 (31.8) 13 (29.5)
Present 40 20 (50.0) 20 (50.0) 14 (35.0)
Significant values are shown in bold.
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tumor showing plasma membrane expression of this
MCT isoform. Therefore, it seems that MCT2 lactate
transport does not have a relevant role in sarcomas, as
observed for other types of tumors [17,20]. When com-
paring tumor grade, MCT1, MCT4 and CD147 were able
to distinguish between low and high grade sarcomas, re-
inforcing the description of a lower glycolytic phenotype
in lower grade than in high grade sarcomas [3-5].The molecular mechanisms underlying MCT expres-
sion in sarcomas were not under investigation in the
present study, however, other studies have addressed this
matter using the human rhabdomyosarcoma cell line RD
[24,26]. Both MCT1 and MCT4 expressions were shown
to be induced by the protein kinase C (PKC) signaling
pathway [24,26], while MCT1 expression was shown to
be inhibited by PKA signaling pathway [24]. However,
additional studies are warranted to unveil the detailed
Figure 2 (See legend on next page.)
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Figure 2 Overall survival curves of soft tissue sarcomas’ patients. The results are stratified according to the immunohistochemical expression
of the different proteins analyzed. Continuous line refers to positive expression while interrupted line refers to negative expression. Plasma
membrane expressions of MCT1 (A) and MCT4 (C) are significantly associated with lower patient’s overall survival, while nuclear expression of
MCT1 shows a strong tendency to be associated with higher patient’s overall survival (B). Plasma membrane expression of CD147 (D) is not
associated with patient’s overall survival, however, plasma membrane co-expression of CD147 with MCT4 (F), but not MCT1 (E), is associated with
lower patient’s overall survival.
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tion, as well as other regulatory mechanisms.
It has been described that the hypoxia-induced emer-
gence of a hyperglycolytic and acid-resistant phenotype
will contribute to the invasiveness of cancer cells [31]. In
this context, MCTs perform a dual role as lactate trans-
porters, by extruding the end product of glycolysis, and
pH regulators, by extruding a proton. Accordingly, in
the present study, patients with disease progression have
a higher likelihood to harbor tumors with plasma mem-
brane expression of MCT1 and MCT4. Importantly,
both MCT1 and MCT4 were able to distinguish between
a group with worse survival (positive group) and a group
with better survival (negative group), pointing to a pos-
sible value of MCTs in prognosis. This is the first study
showing an association of MCTs with soft tissue sar-
coma patient survival, which is in accordance with the
role of these transporters in cancer as well as with their
possible use as cancer therapeutic targets.DNA MergedMCT1
DNA MergedMCT4
DNA MergedCD147
Figure 3 Immunofluorescence for MCT1, MCT4 and CD147 in
MLS-175 cells. The myxoid liposarcoma cell line MLS-175 was used
to evaluate the cellular localization of MCT1, MCT4 and CD147.
MCT1 expression in the nucleus was confirmed, which was partly
accompanied by CD147 expression. MCT4 was found homogeneously
distributed through the cell. Images were obtained using a Zeiss LSM
510 Meta Confocal setup (Carl Zeiss, Oberkochen, Germany) equipped
with a plan-Apochromat 100/1.4 oil objective.CD147, the MCT1 and MCT4 chaperone, is a much
largely studied protein, due to its parallel function as a
matrix metalloproteinase inducer [32]. In fact, CD147
expression has already been previously studied in a co-
hort of high grade soft tissue sarcomas, however, with
no significant prognostic value [33]. In the present study,
as the cohort also included low grade tumors, CD147
was significantly associated with high grade tumors. Im-
portantly, when co-expressed with MCTs, CD147 was
also significantly associated with other poor prognostic
variables and patient lower survival, strengthening the
hypothesis already raised in gastric cancer [34], that the
prognostic value of CD147 is associated with its co-
expression with MCTs, especially with MCT4 in the case
of sarcomas. This suggests that the prognostic value of
CD147 is mainly associated with its function as
chaperone of MCTs, contributing in this way to the
hyperglycolytic and acid-resistant phenotype.
Another major finding in the present study was the
nuclear expression of MCT1, which was confirmed by
immunofluorescence using a sarcoma cell line, and by
cell fractionation, followed by Western blot. To the best
of our knowledge, this is the first study showing nuclear
expression of this protein. As the cellular localization
does not fit with the classic role of this protein as a
transmembrane transporter, this finding suggests the ex-
istence of an additional, not yet described, role of
MCT1. Although interactions with other proteins are
not well described for MCT1, some interactions can beFigure 4 Western blot of MCT1 after cell fractionation. MLS-175
cells were used to extract nuclear and cytosolic proteins to evaluate
the localization of MCT1. Images were obtained using the ChemiDoc
XRS + system (BioRad).
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mechanism underlying MCT1 expression in the nucleus.
In fact, large-scale mapping of human protein-protein
interactions by mass spectrometry shows an interaction
of MCT1 with AP1S1 (clathrin-associated/assembly/
adaptor protein, small 1) [35], which supports a mecha-
nism of endocytosis (clathrin dependent endocytosis)
that is shared by other proteins, like Notch1 and EGFR,
that may alternatively lead to, instead of degradation,
trafficking into the nucleus [36,37]. Therefore, similarly
to other plasma membrane proteins which, upon a
stimulus, can be directed to the nucleus and play add-
itional roles as transcription modulators, we anticipate
that MCT1 may be trafficked to the nucleus to perform
an alternative function, not related to lactate transport
activity. Other evidence on the factors governing MCT
localization like the presence of specific sorting signals
[38] or substrate-induced increase in MCT1 plasma
membrane expression via GPR109A [39] may help to
elucidate the mechanisms leading to MCT1 nuclear
localization. Importantly, the presence of MCT1 in the
nucleus appears to have a very different biological role
than the one currently known, as tumors with nuclear
expression of MCT1 show a completely opposite beha-
vior when comparing to tumors expressing MCT1 in the
plasma membrane; MCT1 nuclear expression was found
to be associated with the lipogenic lineage, low grade tu-
mors and higher overall survival, pointing to a probable
role of this protein as tumor suppressor. Further studies
are warranted to elucidate this possible new role of MCT1.
Conclusions
This work gives an important contribution for the com-
prehension of the metabolic alterations occurring in STS,
herein demonstrated to be dependent on the cell lineage,
showing the value of MCT expression as a predictor of
poor prognosis in these tumors. Importantly, the results
herein presented provide the first evidence for a different
type of MCT1 expression, which may change the current
state of the art in what concerns monocarboxylate trans-
porters, as it seems to be associated with a new biological
role leading to a poor prognosis in STS.
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